Clover Biopharmaceuticals, Ltd. (HKG:2197)

Market Cap	3.71B +1,316.9%
Revenue (ttm)	3.90M -90.9%
Net Income	-228.23M
EPS	-0.18
Shares Out	1.30B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,166,500
Average Volume	4,190,520
Open	2.850
Previous Close	2.860
Day's Range	2.740 - 2.860
52-Week Range	0.193 - 3.200
Beta	2.61
RSI	45.84
Earnings Date	Mar 25, 2026

About Clover Biopharmaceuticals

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China and internationally. The company’s product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; and SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia. It is also developing SCB-...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 257
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2197

Financial Performance

In 2025, Clover Biopharmaceuticals's revenue was 3.51 million, a decrease of -90.88% compared to the previous year's 38.42 million. Losses were -205.09 million, -77.30% less than in 2024.

Financial numbers in CNY